Safety Study of PI-0824 to Treat Pemphigus Vulgaris
- Conditions
- Pemphigus Vulgaris
- Registration Number
- NCT00063752
- Lead Sponsor
- Peptimmune
- Brief Summary
The purpose of this study is to determine if the use of PI-0824 in patients with Pemphigus vulgaris is safe.
- Detailed Description
Pemphigus vulgaris (PV) is an autoimmune disease affecting approximately 40,000 people worldwide. People with PV produce antibodies that attack the cells of the skin, resulting in blisters which, if left untreated, can lead to devastating infections and discomfort. Currently, most doctors who treat patients with PV will prescribe high-dose steroids and drugs that suppress the immune system in an effort to decrease the production of these antibodies. Unfortunately these medications are associated with serious and difficult side effects that often result in the discontinuation of their use. Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824. The goal of this therapy is to reduce the production of antibodies that cause PV blisters by acting only on the disease causing components of the immune system. It is hoped that use of PI-0824 will reduce or potentially eliminate the need for high dose steroids and drugs that suppress the immune system.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 15
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (8)
East Coast Clinical Research
🇺🇸Salisbury, Massachusetts, United States
Long Island Jewish Medical Center
🇺🇸New Hyde Park, New York, United States
University of California San Francisco
🇺🇸San Francisco, California, United States
NYU School of Medicine
🇺🇸New York, New York, United States
Johns Hopkins School of Medicine
🇺🇸Baltimore, Maryland, United States
University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Stony Brook Dermatology Associates
🇺🇸East Setauket, New York, United States
Case Western Reserve University
🇺🇸Cleveland, Ohio, United States